EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma

INTRODUCTION: It has been well established that EGFR Thr790Met is one of the major resistance mechanisms to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). Nevertheless, whether EGFR Thr790Leu (T790L), which shares the mutation site of Thr790 with EGFR Thr790Met, mediates resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Chan, Zhang, Wei, Xiong, Li-Wen, Cai, Xu-Wei, Teng, Hao-Hua, Zhao, Rui-Ying, Shang, Zhan-Xian, Han-Zhang, Han, Zhang, Lu, Yan, Li, Chen, Zhi-Qiu, Han, Yu-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474199/
https://www.ncbi.nlm.nih.gov/pubmed/34590035
http://dx.doi.org/10.1016/j.jtocrr.2021.100185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474199/
https://www.ncbi.nlm.nih.gov/pubmed/34590035
http://dx.doi.org/10.1016/j.jtocrr.2021.100185

Ejemplares similares